Caffeine and progression of Parkinson disease: A deleterious interaction with creatine

David K. Simon, Cai Wu, Barbara C. Tilley, Anne Marie Wills, Michael J. Aminoff, Jacquelyn Bainbridge, Robert A. Hauser, Jay S. Schneider, Saloni Sharma, Carlos Singer, Caroline M. Tanner, Daniel Truong, Pei Shieen Wong

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Objective: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake. Methods: Data were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified ParkinsonDisease Rating Scale score and the interaction of this association with creatine intake were assessed. Results: Caffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine. Conclusions: This is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.

Original languageEnglish (US)
Pages (from-to)163-169
Number of pages7
JournalClinical neuropharmacology
Volume38
Issue number5
DOIs
StatePublished - Oct 1 2015

Keywords

  • Adenosine A2a receptor antagonist: LS1
  • Association
  • Caffeine
  • Clinical study
  • Coffee
  • Creatine
  • Interaction
  • Movement disorders
  • NET-PD
  • Neuroprotection
  • Parkinson disease
  • Progression
  • Supplement

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Caffeine and progression of Parkinson disease: A deleterious interaction with creatine'. Together they form a unique fingerprint.

  • Cite this

    Simon, D. K., Wu, C., Tilley, B. C., Wills, A. M., Aminoff, M. J., Bainbridge, J., Hauser, R. A., Schneider, J. S., Sharma, S., Singer, C., Tanner, C. M., Truong, D., & Wong, P. S. (2015). Caffeine and progression of Parkinson disease: A deleterious interaction with creatine. Clinical neuropharmacology, 38(5), 163-169. https://doi.org/10.1097/WNF.0000000000000102